Associate Scientist, Next Generation Manufacturing

CARGO is seeking a highly motivated Associate Scientist to join the team researching next-generation manufacturing approaches that enhance cellular fitness while also increasing the probability of successful manufacturing of CAR T-cells.
At CARGO, we recognize the crucial impact of the manufacturing process on the efficacy and performance of these cells in patients.
Building on CARGO’s preclinical, clinical, and manufacturing experience, the Research Next Generation Manufacturing (NGM) team at CARGO aims to unlock transformational improvements to the manufacturing of CAR T-cells by evaluating and implementing cutting edge technologies in the cell therapy space.
For this position, we seek a scientist who is driven to work collaboratively across multidisciplinary R&D teams.
A strong background in cell biology, immunology, translational research, and knowledge of cell therapy manufacturing technologies is preferred.
We seek candidates who will not be constrained by dogmatic thinking, and who are curious and interested in exploring novel technologies to alter the therapeutic performance of T-cells.
Working closely with the NGM team, the successful candidate will be responsible for the experimental execution and evaluation of next-generation manufacturing processes in research scale model systems.
In partnership with the Technical Operations manufacturing team, this role will make key contributions towards delivering the next generation of CAR T-cells to patients.
The role is based in San Mateo, CA.
WHAT YOU’LL DO AT CARGO THERAPEUTICS Evaluate internal and external technologies focused on delivering CAR T-cell products with improved product characteristics and enhanced durable functionality Drive generation and characterization of autologous and allogeneic CAR T-cell lots using standard and novel NGM processes including: work with primary donor cells, lentiviral transduction, T-cell expansion and culture, gene editing, and cell line maintenance Evaluate NGM CAR T-cell products using advanced functional in vitro assays designed to challenge conventional cell therapies Frequent use of flow cytometry, cell counting, and co-culture effector assays; cell sorting experience is a plus Engage in cross-functional collaboration, presenting data seamlessly across teams, to ensure the successful delivery of the next generation of cellular therapies to patients Stay abreast of the latest advancements in the field by actively reading scientific literature and continuously expanding your skill set through learning and mastering new techniques Champion efficiency by evaluating and implementing automation solutions whenever possible THE RIGHT STUFF: Required Experience & Qualifications Bachelor's or Master’s degree in a relevant scientific discipline (e.
g.
biology, pharmacology, immunology) with 5+ years of experience is required Experience with CAR T-cell therapy and related fields is preferred The successful candidate will share our keen sense of curiosity, inventive spirit, and determination to advance cell therapy Exhibit proficiency in CAR T-cell functional assays, flow cytometry, cytokine analysis, and cell culture Previous experience with high-throughput assays and automation implementation is a significant plus Ability to thrive in a strongly collaborative environment, demonstrating a commitment to solving the most challenging multidisciplinary issues in cell therapy Navigate the fast-paced environment at CARGO with the ability to work independently and as part of a team, showcasing a meticulous attention to detail PAY RANGE The combined pay range for this role is $88,000 - $121,000.
Title and salary will be based on our assessment of skills and experience relevant to our needs for the role.
ABOUT CARGO THERAPEUTICS CARGO Therapeutics, Inc.
is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients.
CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply.
CARGO is currently evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.
CARGO also plans to evaluate CRG-022 in patients at earlier stages of disease, including LBCL and other hematologic malignancies.
Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion.
CARGO’s founders are pioneers and world-class experts in CAR T-cell therapy, and its team has significant experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products.
For more information, please visit the CARGO Therapeutics website at https://cargo-tx.
com/.
Join us to help make a difference! EEO & EMPLOYMENT ELIGIBILITY CARGO Therapeutics, Inc.
is committed to building a diverse, equitable, and inclusive company.
We provide equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability, or veteran status.
CARGO Therapeutics, Inc.
also complies with all applicable national, state, and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification required of applicable law.
CARGO Therapeutics requires all new hires to be fully vaccinated against COVID-19 as of their start date.
This requirement is a condition of employment at CARGO Therapeutics, and it applies regardless of whether the position is located at a CARGO Therapeutics site or is fully remote.
If you are unable to receive the vaccine due to a disability or serious medical condition, or because it is prohibited because of your sincerely held religious beliefs, you will have an opportunity to request a reasonable accommodation.